AIM ImmunoTech (AIM) Competitors $0.26 +0.00 (+0.46%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AIM vs. RPHM, SYRS, STTK, MURA, BRNS, KRON, VOR, IMRX, CVM, and VHAQShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Reneo Pharmaceuticals (RPHM), Syros Pharmaceuticals (SYRS), Shattuck Labs (STTK), Mural Oncology (MURA), Barinthus Biotherapeutics (BRNS), Kronos Bio (KRON), Vor Biopharma (VOR), Immuneering (IMRX), CEL-SCI (CVM), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Reneo Pharmaceuticals Syros Pharmaceuticals Shattuck Labs Mural Oncology Barinthus Biotherapeutics Kronos Bio Vor Biopharma Immuneering CEL-SCI Viveon Health Acquisition Reneo Pharmaceuticals (NASDAQ:RPHM) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Do insiders and institutionals have more ownership in RPHM or AIM? 91.0% of Reneo Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 17.9% of Reneo Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is RPHM or AIM more profitable? Reneo Pharmaceuticals has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -13,952.74%. Reneo Pharmaceuticals' return on equity of -62.52% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Reneo PharmaceuticalsN/A -62.52% -56.36% AIM ImmunoTech -13,952.74%-269.04%-141.74% Do analysts recommend RPHM or AIM? Reneo Pharmaceuticals presently has a consensus price target of $11.01, suggesting a potential upside of 505.08%. AIM ImmunoTech has a consensus price target of $3.00, suggesting a potential upside of 1,076.47%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than Reneo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reneo Pharmaceuticals 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.88AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RPHM or AIM? AIM ImmunoTech received 38 more outperform votes than Reneo Pharmaceuticals when rated by MarketBeat users. Likewise, 82.86% of users gave AIM ImmunoTech an outperform vote while only 57.14% of users gave Reneo Pharmaceuticals an outperform vote. CompanyUnderperformOutperformReneo PharmaceuticalsOutperform Votes2057.14% Underperform Votes1542.86% AIM ImmunoTechOutperform Votes5882.86% Underperform Votes1217.14% Which has more volatility and risk, RPHM or AIM? Reneo Pharmaceuticals has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Which has stronger earnings & valuation, RPHM or AIM? AIM ImmunoTech has higher revenue and earnings than Reneo Pharmaceuticals. Reneo Pharmaceuticals is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReneo PharmaceuticalsN/AN/A-$77.39M-$2.17-0.84AIM ImmunoTech$200K74.80-$28.96M-$0.57-0.45 Does the media favor RPHM or AIM? In the previous week, Reneo Pharmaceuticals' average media sentiment score of 0.00 equaled AIM ImmunoTech'saverage media sentiment score. Company Overall Sentiment Reneo Pharmaceuticals Neutral AIM ImmunoTech Neutral SummaryAIM ImmunoTech beats Reneo Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$14.96M$3.15B$5.33B$19.27BDividend YieldN/A1.77%5.07%3.53%P/E Ratio-0.4516.44128.4043.27Price / Sales74.80321.081,491.7714.55Price / CashN/A149.0539.5620.89Price / Book1.284.024.765.40Net Income-$28.96M-$42.25M$118.92M$985.39M7 Day Performance-5.13%1.81%-0.39%-0.70%1 Month PerformanceN/A8.56%6.06%-0.86%1 Year Performance-43.71%35.10%38.23%28.60% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.3085 of 5 stars$0.26+0.5%$3.00+1,049.0%-43.7%$15.32M$201,000.00-0.4620RPHMReneo Pharmaceuticals2.3269 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap DownSYRSSyros Pharmaceuticals4.6718 of 5 stars$2.25-10.7%$5.00+122.2%-5.2%$60.32M$4.15M-0.52120Earnings ReportAnalyst ForecastNews CoverageGap DownSTTKShattuck Labs3.5902 of 5 stars$1.25-0.7%$8.67+592.9%-22.4%$59.70M$1.66M-0.68100MURAMural Oncology3.8127 of 5 stars$3.50-0.6%$16.00+357.1%N/A$59.64MN/A-0.34119BRNSBarinthus Biotherapeutics3.487 of 5 stars$1.51+1.4%$5.83+286.3%N/A$59.53M$800,000.00-0.92107Short Interest ↓News CoverageKRONKronos Bio3.5664 of 5 stars$0.97-0.2%$4.13+326.0%+17.4%$58.39M$6.29M-0.56100Short Interest ↓News CoverageVORVor Biopharma1.6508 of 5 stars$0.85+1.2%$10.92+1,184.3%-51.4%$58.14MN/A-0.49140Upcoming EarningsNews CoverageIMRXImmuneering3.7837 of 5 stars$1.94+4.4%$12.60+548.6%-71.1%$57.60M$320,000.00-1.0260Short Interest ↓News CoveragePositive NewsCVMCEL-SCIN/A$0.90+1.1%N/A-47.5%$57.42MN/A-1.5543VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.60MN/A0.002High Trading Volume Related Companies and Tools Related Companies RPHM Alternatives SYRS Alternatives STTK Alternatives MURA Alternatives BRNS Alternatives KRON Alternatives VOR Alternatives IMRX Alternatives CVM Alternatives VHAQ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:AIM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
